Core Insights - The establishment of the commercial insurance innovative drug directory marks the entry of China's medical security system into a "dual directory" era, enhancing the coverage of innovative drugs [1][2] - The 2025 National Medical Insurance Drug List has added 114 new drugs, including 50 innovative drugs, addressing gaps in basic medical insurance for major diseases and rare conditions [1] - The total number of drugs in the National Medical Insurance Drug List has increased to 3,253, significantly improving coverage for critical areas such as oncology, chronic diseases, and rare diseases [1] Group 1 - The dual directory system aims to better meet patient medication needs, support the development of innovative drugs, and alleviate the burden on basic medical insurance [2] - The inclusion of innovative drugs in the commercial insurance directory is expected to create a win-win situation for pharmaceutical companies and insurance providers [2] - The first commercial insurance products to adopt the innovative drug directory are anticipated to be community health insurance plans, with high-value drugs like CAR-T already included in some local plans [2] Group 2 - The Shanghai "new group insurance" is expected to launch in December, potentially becoming the first commercial health insurance product to incorporate the innovative drug directory [2] - The measures to promote the high-quality development of commercial health insurance are aimed at supporting the innovation of the biopharmaceutical industry [2]